NGNE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
36.7M
+10.0%
33.3M
+21.1%
27.5M
+15.7%
23.8M
-8.8%
26.1M
R&D
25.5M
+1.3%
25.1M
+21.9%
20.6M
+19.7%
17.2M
-11.0%
19.4M
SG&A
11.2M
+36.6%
8.2M
+19.0%
6.9M
+5.1%
6.6M
-2.4%
6.7M
Operating Income
-36670000
-10.0%
-33349000
-21.1%
-27529000
-15.7%
-23798000
+8.8%
-26081000
EBITDA
-35857000
-10.3%
-32502000
-21.5%
-26753000
-16.1%
-23034000
+9.1%
-25327000
Net Income
-34488000
-11.5%
-30934000
-25.1%
-24735000
-18.0%
-20953000
+4.8%
-22016000
EPS (Basic)
$-1.53
-10.1%
$-1.39
-24.1%
$-1.12
-13.1%
$-0.99
+5.7%
$-1.05
EPS (Diluted)
$-1.53
-10.1%
$-1.39
-24.1%
$-1.12
-13.1%
$-0.99
+5.7%
$-1.05
Shares (Diluted)
22.6M
+1.1%
22.3M
+1.0%
22.1M
+4.3%
21.2M
+0.5%
21.1M
Neurogene (NGNE) โ€” Financials